|
About 30 percent of patients with severe hemophilia A develop an immune response to the therapeutic blood clotting agent—Factor VIII—used to treat it. The Josephson Laboratory has ongoing projects that focus on developing faster and more reliable methods of eliminating that response. The lab is also studying the use of stem cells to treat a rare, inherited bone marrow failure syndrome.
- Developing better treatments to prevent and eliminate immune responses to Factor VIII
- Developing strategies for treating bone marrow failure syndromes with stem cells taken from the patient and corrected
- Read more
- Joined the Blood Center in 2002
- Director of the Blood Center's Hemophilia Treatment Center
- Affiliated with the Division of Hematology at the University of Washington School of Medicine
|
|
Neil C. Josephson, MD
Director of Hemophilia Care Program
Puget Sound Blood Center
Associate Member
Puget Sound Blood Center
Research Institute
Associate Member of Medicine
Division of Hematology
University of Washington
School of Medicine
Puget Sound Blood Center
Research Institute
1551 Eastlake Avenue E.
Seattle, WA 98102
Email: neiljo@psbc.org
Phone: (206) 568-2212
FAX: (866) 287-3940
Daphne Sanders
Admin Support Specialist II
Email: daphnes@psbc.org
Phone: (206) 292-6507
FAX: (206) 292-4094 |